Competitive AdvantageIf sotatercept's label includes certain restrictions, it could create a more advantageous product positioning for AV-101 as a potentially safe and inhaled PAH option.
Drug Development And ApprovalAV-101 is anticipated to be eligible for a 505(b)(2) pathway, potentially streamlining its development and approval process.
Market PotentialThere is potential for upside to the conservative pricing estimates of AV-101, which may lead to higher peak sales projections if the drug is competitive in safety and efficacy.